Twist Bioscience reported a record-breaking fourth quarter in QQ4 2024 with revenue of $84.7 million, up 27% year-over-year and 4% sequentially, contributing to a full-year revenue of approximately $313 million (management provided $313m in 2024 revenue, with executive commentary noting a broader 2024 revenue trajectory). Gross margin for the quarter rose to 45.1% (FY2024 gross margin 42.6%), driven by the Express portfolio and margin-expansion initiatives, including operating-efficiency programs and supply-chain optimization. The company posted an adjusted EBITDA loss of roughly $17 million in Q4 and about $93.5 million for the full year, reflecting ongoing investments in growth initiatives and automation as Twist targets adjusted EBITDA breakeven in fiscal 2025. The balance sheet remains solid with roughly $276.4 million in cash, cash equivalents and short-term investments at quarter-end, and zero near-term debt maturities, positioning Twist to fund R&D and product launches while progressing toward profitability. Management remains confident in long-term growth drivers, including Express Genes, MRD/NGS tools, biopharma services, and a strategic push into proprietary enzymes and DNA data storage. The 2025 guidance calls for revenue of $367–$377 million, gross margin around 48%, and an adjusted EBITDA loss of $60–$65 million, with Q1 2025 revenue about $87 million and ongoing sequential margin improvement toward the 50% gross margin target by the end of fiscal 2025.
Key takeaways for investors: (1) Growth momentum is sustained across SynBio (Express), NGS, and Biopharma, underpinned by a diversified product portfolio and expanding customer base; (2) Operational excellence and automation are driving margin expansion, with a clear plan to reach EBITDA breakeven and move toward cash-flow positive growth; (3) The company is pursuing meaningful longer-term opportunities in proprietary enzymes and DNA data storage, which could unlock additional margin expansion and large addressable markets, albeit with execution risk and longer development windows.